Binds to IL-5, inhibiting eosinophil growth, activation, and survival.

Indicated for patients ≥18 years with severe eosinophilic asthma as add-on therapy.

Dosage: 3 mg/kg every 4 weeks.

Infusion duration: 20–50 minutes.

Common (>2%): Oropharyngeal pain.

CPK Elevation and muscle-related symptoms:

• Myalgia (1%)

• Elevated CPK without symptoms (up to 20%)

Immunogenicity: Anti-drug antibodies developed in ~5% of patients; no impact observed on efficacy or safety.

CINQAIR is contraindicated in patients who have known hypersensitivity to reslizumab or any of its excipients.

Anaphylaxis 

Not for acute asthma symptoms.

Malignancy – higher incidence (0.6% vs. 0.3%) in treated vs placebo groups.

Corticosteroid Tapering – must be gradual.

Helminth Infections – treat prior to therapy; discontinue if unresponsive during treatment.